A detailed history of Jefferies Financial Group Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Jefferies Financial Group Inc. holds 278,622 shares of BMY stock, worth $15.8 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
278,622
Previous 231,054 20.59%
Holding current value
$15.8 Million
Previous $9.6 Million 50.27%
% of portfolio
0.11%
Previous 0.11%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $1.89 Million - $2.46 Million
47,568 Added 20.59%
278,622 $14.4 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $4.51 Million - $5.93 Million
111,992 Added 94.06%
231,054 $9.6 Million
Q1 2024

May 13, 2024

SELL
$47.98 - $54.4 $3.67 Million - $4.17 Million
-76,577 Reduced 39.14%
119,062 $6.46 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $3.19 Million - $3.8 Million
65,723 Added 50.59%
195,639 $10 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $5.91 Million - $6.6 Million
102,023 Added 365.77%
129,916 $7.54 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $9.82 Million - $10.9 Million
-154,100 Reduced 84.67%
27,893 $1.78 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $7.96 Million - $9.03 Million
121,207 Added 199.4%
181,993 $12.6 Million
Q4 2022

Sep 21, 2023

BUY
$68.48 - $81.09 $2.13 Million - $2.52 Million
31,107 Added 111.52%
59,000 $4.24 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $4.16 Million - $4.93 Million
60,786 New
60,786 $4.37 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $121B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Jefferies Financial Group Inc. Portfolio

Follow Jefferies Financial Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.